

Michigan Pharmacy and Therapeutics Committee
Meeting of March 4, 2008, 6PM
Kellogg Center, East Lansing MI
DRAFT DRAFT DRAFT Minutes DRAFT DRAFT DRAFT

Welcome and Introductions

Committee members present: P. Dake, MD, J. Fiechtner, MD, J. Arend, PharmD, D. VanLoo, PharmD, R. Bradley, DO, R. Rogers, MD, K. Nedd, MD, J. Dillon, MD, G. Perri, MD

State staff present: S. Moran, RN, T. O'Keefe, RN, T. Welch, D. Eggleston, MD, J. Coleman

First Health staff: A. Paul, RPh

Approval of Minutes of December 2007 Meeting

The draft minutes were approved as written

New Drugs

Following presentation, discussion and review, the Committee recommends to the Department the following:

Perforomist: Add to the Michigan Pharmaceutical Product List (MPPL) and to the Preferred Drug List (PDL) with prior authorization

Xyzal: Add to the MPPL and to the PDL with prior authorization

Exforge: Add to the MPPL and to the PDL without prior authorization

Kuvan: Add to the MPPL

Tasigna: Add to the MPPL

Line Extensions

Lipofen: Add to the MPPL and to the PDL with prior authorization

Tri-zyme: Add to the MPPL

Coraz lotion kit: Add to the MPPL with prior authorization

Review of PDL Classes

Following review and discussion, the Committee recommends to the Department:

ACE Inhibitors

No change to the current classification of the drugs in this class

Antihypertensive Combinations-ACEI-CCB

No change to the current classification of the drugs in this class

Angiotensin Receptor Antagonists

No change to the current classification of the drugs in this class

Direct Renin Inhibitors

No change to the current classification of the drug in this class

Beta blockers

No change to the current classification of the drugs in this class

Calcium Channel Blockers-Dihydropyridine

No change to the current classification of the drugs in this class

Calcium Channel Blockers-Non-Dihydropyridines

No change to the current classification of the drugs in this class

Lipotropic-Antihypertensive Combination

No change to the current classification of the drug in this class

Lipotropics-Non Statins: Fibrin Acid Derivatives

No change to the current classification of the drugs in this class

Lipotropics: Non Statins

No change to the current classification of the drugs in this class

Lipotropics: Statins

Create an electronic edit at point of sale to allow Advicor prescriptions without formal prior authorization if the patient has been on either lovastatin or niacin product in the past

No change to the other drug classifications in this class

Lipotropics: Niacin Derivatives

No change to the current classification of the drugs in this class

Lipotropics: Other

Create an electronic edit at point of sale to allow Lovaza (Omacor) prescriptions without formal prior authorization if the patient has been on a statin drug

Keep Zetia available without prior authorization at this time

Public Comment:

The following individuals presented to the Committee:

C. Summers, PhD, Daiichi Sankyo, Azor

C. Farnum, DO, JNJ, Levaquin

N. Bieszk, Sanofi-Aventis, Xyzal

M. Bolan, MD, Forest, Bystolic

L. Bollinger, PharmD, Roche, Pegasys

H. Quinones, PhD, Astrazeneca, Symbicort, Pulmicort, Rhinocort

T. Edwards, PhD GSK, Respiratory products

G. Tully, Biomarin, Kuvan

S. Hoffman, PharmD, Abbott, Azmacort

N. Wood, MD, Schering Plough, Zetia, Vytarin

Next Meeting: Tuesday, June 3, 2008